Hem › Neuroblastom › Texas
Kliniska studier för Neuroblastom i Texas
15 studier för Neuroblastom söker deltagare vid platser i Texas.
Städer i Texas
Officiell studietext (engelska)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- och 10 fler
RekryterarFas 3
Upp till ålder 30 · Alla kön · Uppdaterad 2 okt. 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
RekryterarFas 1/2
6 Months – 25 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
RekryterarFas 2
Upp till ålder 22 · Alla kön · Uppdaterad 4 sep. 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
RekryterarFas 1/2
Upp till ålder 26 · Alla kön · Uppdaterad 3 sep. 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
RekryterarFas 1/2
Upp till ålder 30 · Alla kön · Uppdaterad 3 sep. 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
RekryterarFas 2
Ålder 1 till 21 · Alla kön · Uppdaterad 3 sep. 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- och 8 fler
RekryterarFas 3
365 Days – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
RekryterarFas 2
12 Months – 21 Years · Alla kön · Uppdaterad 12 aug. 2026 · NCT05489887PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
RekryterarFas 1/2
Ålder 1 till 30 · Alla kön · Uppdaterad 22 juli 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
RekryterarFas 1
Ålder 1 till 24 · Alla kön · Uppdaterad 21 juli 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
RekryterarFas 2
Ålder 1 till 31 · Alla kön · Uppdaterad 20 juli 2026 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
RekryterarObservationsstudie
31 Days – 99 Years · Alla kön · Uppdaterad 23 mars 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Rekryterar
Upp till ålder 17 · Alla kön · Uppdaterad 10 feb. 2026 · NCT06831552GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
- Texas Children's Hospital, Houston
RekryterarFas 1
Ålder 1 till 21 · Alla kön · Uppdaterad 19 sep. 2025 · NCT03294954Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.